No Data
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial Of First Oral TNF-Alpha Inhibitor Candidate Isomyosamine For Treatment For Chronic Inflammation Associated With Muscle Loss In Patients Who Undergone Hip Or Femur Fracture Repair Surgery
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
Express News | Tnf Pharmaceuticals Initiates Phase 2B Clinical Trial of First Oral Tnf-Alpha Inhibitor
Trump Floats 25% Tariffs on Autos, Chips, Pharmaceuticals
TNF Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Initiated the First in a Series of Studies to Evaluate the Impact of Isomyosamine.
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
)